JP2013535436A - 医薬組成物及び治療方法 - Google Patents

医薬組成物及び治療方法 Download PDF

Info

Publication number
JP2013535436A
JP2013535436A JP2013519178A JP2013519178A JP2013535436A JP 2013535436 A JP2013535436 A JP 2013535436A JP 2013519178 A JP2013519178 A JP 2013519178A JP 2013519178 A JP2013519178 A JP 2013519178A JP 2013535436 A JP2013535436 A JP 2013535436A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antibody
composition according
activation
cannabinoid receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013519178A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013535436A5 (enExample
Inventor
イリイチ・エプシテイン オレグ
アレクサンドロヴナ・セルゲーエワ スヴェトラーナ
フョードロヴナ・ドルゴヴィフ リュドミーラ
アナトリエヴナ・ケイフェツ イリーナ
レオニドヴナ・ドゥギナ ユリア
アレクサンドロヴナ・ザボロトネヴァ ユリア
アレクサンドロヴィッチ・タラソワ セルゲイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44899164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2013535436(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU2010129289/15A external-priority patent/RU2552221C2/ru
Priority claimed from RU2010130350/15A external-priority patent/RU2533224C2/ru
Priority claimed from RU2011122407A external-priority patent/RU2610438C2/ru
Application filed by Individual filed Critical Individual
Publication of JP2013535436A publication Critical patent/JP2013535436A/ja
Publication of JP2013535436A5 publication Critical patent/JP2013535436A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Addiction (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013519178A 2010-07-15 2011-07-15 医薬組成物及び治療方法 Pending JP2013535436A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
RU2010129289 2010-07-15
RU2010129289/15A RU2552221C2 (ru) 2010-07-15 2010-07-15 Способ лечения ожирения и сопутствующих метаболических расстройств и лекарственное средство для лечения ожирения и сопутствующих метаболических расстройств
RU2010130350 2010-07-21
RU2010130350/15A RU2533224C2 (ru) 2010-07-21 2010-07-21 Способ лечения зависимости от психоактивных веществ, алкоголизма и табакокурения и лекарственное средство для лечения зависимости от психоактивных веществ, алкоголизма и табакокурения
RU2011122407 2011-06-02
RU2011122407A RU2610438C2 (ru) 2011-06-02 2011-06-02 Способ лечения патологического синдрома и лекарственное средство центрального и периферического действия для лечения патологического синдрома
PCT/IB2011/002404 WO2012007847A2 (en) 2010-07-15 2011-07-15 Pharmaceutical compositions and methods of treatment

Publications (2)

Publication Number Publication Date
JP2013535436A true JP2013535436A (ja) 2013-09-12
JP2013535436A5 JP2013535436A5 (enExample) 2014-04-24

Family

ID=44899164

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013519178A Pending JP2013535436A (ja) 2010-07-15 2011-07-15 医薬組成物及び治療方法

Country Status (30)

Country Link
US (1) US8865163B2 (enExample)
EP (1) EP2593477A2 (enExample)
JP (1) JP2013535436A (enExample)
KR (1) KR20140012009A (enExample)
CN (1) CN103124742A (enExample)
AR (1) AR082246A1 (enExample)
AU (1) AU2011278040B2 (enExample)
BR (1) BR112013000841A2 (enExample)
CA (1) CA2805091A1 (enExample)
CL (1) CL2013000098A1 (enExample)
CZ (1) CZ2013104A3 (enExample)
DE (1) DE112011102349T5 (enExample)
DK (1) DK201370078A (enExample)
EA (1) EA029400B1 (enExample)
EE (1) EE05760B1 (enExample)
ES (1) ES2542042R1 (enExample)
FI (1) FI20135146L (enExample)
FR (1) FR2962653A1 (enExample)
GB (1) GB2496076B (enExample)
IT (1) ITTO20110641A1 (enExample)
LT (1) LT5987B (enExample)
MX (1) MX361778B (enExample)
MY (1) MY158183A (enExample)
NO (1) NO20130219A1 (enExample)
NZ (1) NZ606768A (enExample)
PE (1) PE20131338A1 (enExample)
PH (1) PH12013500109A1 (enExample)
SE (1) SE1350179A1 (enExample)
SG (1) SG187037A1 (enExample)
WO (1) WO2012007847A2 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013533269A (ja) * 2010-07-21 2013-08-22 イリイチ・エプシテイン オレグ 組み合わせ医薬組成物及び呼吸器の疾患又は状態に関連する疾患及び状態を治療する方法
JP2013533268A (ja) * 2010-07-21 2013-08-22 イリイチ・エプシテイン オレグ 糖尿病及び代謝障害を治療する組み合わせ医薬組成物及び方法
JP2013536174A (ja) * 2010-07-21 2013-09-19 イリイチ・エプシテイン オレグ 組み合わせ医薬組成物並びに回転性めまい、動揺病及び自律神経血管ジストニアを治療する方法
JP2013537532A (ja) * 2010-08-06 2013-10-03 イリイチ・エプシテイン オレグ 感染性疾患を治療及び予防する組み合わせ医薬組成物及び方法
JP2016512893A (ja) * 2013-03-18 2016-05-09 イリイチ・エプシテイン オレグ 医薬の調節効力の程度を測定する方法
JP2018150322A (ja) * 2010-07-15 2018-09-27 イリイチ・エプシテイン オレグ 組み合わせ医薬組成物及び泌尿生殖器系障害を治療する方法
JP2022545178A (ja) * 2019-08-29 2022-10-26 イリイチ・エプシテイン オレグ 感染症を治療するための医薬及び方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
CA2804966A1 (en) 2010-07-15 2012-01-19 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
CN103154028A (zh) 2010-07-15 2013-06-12 奥列格·伊里奇·爱泼斯坦 复合药物组合物以及对神经退行性疾病相关的疾病或病症进行治疗的方法
CN103119061A (zh) 2010-07-21 2013-05-22 奥列格·伊里奇·爱泼斯坦 治疗注意力不足过动症的方法
RU2013111961A (ru) * 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
KR102731863B1 (ko) * 2014-03-27 2024-11-19 버드 락 바이오, 인크. 인간 카나비노이드 1(cb1) 수용체 결합 항체
CN104524568B (zh) * 2015-01-08 2018-04-20 中国人民解放军第二军医大学 一种治疗肥胖症的药物组合物及其应用
CA3000167A1 (en) * 2015-09-30 2017-04-06 Bird Rock Bio, Inc. Antibodies that bind human cannabinoid 1 (cb1) receptor
CH721975A1 (de) * 2024-07-15 2026-01-30 Ilyich Epshtein Oleg Verfahren für den Erhalt von Kosmetik- und therapeutischen Kosmetikmitteln

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030099636A1 (en) * 2000-06-20 2003-05-29 Epshtein Oleg Iliich Curing method for pathologic syndrome and medicinal preparation
JP2007527893A (ja) * 2004-03-09 2007-10-04 アサーム Ｃｂ１受容体のアンタゴニストの使用及びタンパク質をコードする核酸配列の使用、そして肝臓病治療方法
JP2009530271A (ja) * 2006-03-13 2009-08-27 オレグ イリッチ エプシュテイン 固体の経口投与形態の医薬組成物、及びその製造方法
JP2009539827A (ja) * 2006-06-06 2009-11-19 オレグ イリッチ エプシュテイン 肥満、真性糖尿病及び耐糖能異常を伴う疾患の治療用薬剤
JP2010507589A (ja) * 2006-10-23 2010-03-11 イーライ リリー アンド カンパニー Ｃｂｌ’受容体モジュレーターとしての１，５−ジフェニル−３−ピリジニルアミノ−１，５−ジヒドロピロリジン−２−オン
JP2010132631A (ja) * 2008-11-04 2010-06-17 Bizen Chemical Co Ltd カンナビノイド受容体のインバースアゴニストおよびアンタゴニスト活性を有する組成物
JP2013532182A (ja) * 2010-07-15 2013-08-15 イリイチ・エプシテイン オレグ 組み合わせ医薬組成物及び神経変性疾患に関連する疾患又は状態を治療する方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
WO1997028776A1 (en) 1996-02-12 1997-08-14 Oleg Iliich Epshtein Medicament and method of treating an organism with medicaments
US5849528A (en) 1997-08-21 1998-12-15 Incyte Pharmaceuticals, Inc.. Polynucleotides encoding a human S100 protein
RU2156621C1 (ru) 1999-03-04 2000-09-27 Эпштейн Олег Ильич Нейротропное лекарственное средство
RU2201255C1 (ru) 2001-12-26 2003-03-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции сосудистого тонуса
RU2209084C1 (ru) * 2001-12-26 2003-07-27 Эпштейн Олег Ильич Лекарственное средство и способ лечения депрессивных расстройств
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
UA76640C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Спосіб корекції патологічних імунних реакцій та гомеопатичний лікарський засіб
UA76639C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
GB2414670B (en) 2003-03-14 2008-03-19 Nutrition Res Inc Homeopathic formulations useful for treating pain and/or inflammation
US20050100513A1 (en) * 2003-11-10 2005-05-12 Watkins Mary B. Homeopathic method and system for treating nicotine addiction
RU2437678C2 (ru) 2006-06-06 2011-12-27 Олег Ильич Эпштейн Лекарственное средство для перорального лечения ожирения и способ получения твердой лекарственной формы для пероральной терапии ожирения
RU2438707C2 (ru) 2006-06-06 2012-01-10 Олег Ильич Эпштейн Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе
EP1985295A1 (en) * 2007-04-04 2008-10-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Selective inhibitors of CB2 receptor expression and/or activity for the treatment of obesity and obesity-related disorders
CN103096927A (zh) 2010-07-15 2013-05-08 奥列格·伊里奇·爱泼斯坦 复合药物组合物以及治疗胃肠道功能性疾病或病症的方法
CN103119061A (zh) 2010-07-21 2013-05-22 奥列格·伊里奇·爱泼斯坦 治疗注意力不足过动症的方法
SE1350212A1 (sv) 2010-07-21 2013-04-22 Oleg Iliich Epshtein Farmaceutisk kombinationskomposition och meto der för behandling av diabetes och metabola rubbningar
CA2805943A1 (en) 2010-07-21 2012-01-26 Oleg Iliich Epshtein Use of homeopathically potentized antibodies to brain-specific protein s-100 and to endothelial no synthase for treating alzheimer's disease
ITTO20110634A1 (it) 2010-07-21 2012-01-22 Oleg Iliich Epshtein Metodo per trattare patologie organiche del sistema nervoso, la sindrome psicoorganica e l'encefalopatia
ITTO20110630A1 (it) 2010-07-21 2012-01-22 Oleg Iliich Epshtein Composizioni farmaceutiche di combinazione e metodo per trattare vertigini, cinetosi e distonia vascolare vegetativa

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030099636A1 (en) * 2000-06-20 2003-05-29 Epshtein Oleg Iliich Curing method for pathologic syndrome and medicinal preparation
JP2007527893A (ja) * 2004-03-09 2007-10-04 アサーム Ｃｂ１受容体のアンタゴニストの使用及びタンパク質をコードする核酸配列の使用、そして肝臓病治療方法
JP2009530271A (ja) * 2006-03-13 2009-08-27 オレグ イリッチ エプシュテイン 固体の経口投与形態の医薬組成物、及びその製造方法
JP2009539827A (ja) * 2006-06-06 2009-11-19 オレグ イリッチ エプシュテイン 肥満、真性糖尿病及び耐糖能異常を伴う疾患の治療用薬剤
JP2010507589A (ja) * 2006-10-23 2010-03-11 イーライ リリー アンド カンパニー Ｃｂｌ’受容体モジュレーターとしての１，５−ジフェニル−３−ピリジニルアミノ−１，５−ジヒドロピロリジン−２−オン
JP2010132631A (ja) * 2008-11-04 2010-06-17 Bizen Chemical Co Ltd カンナビノイド受容体のインバースアゴニストおよびアンタゴニスト活性を有する組成物
JP2013532182A (ja) * 2010-07-15 2013-08-15 イリイチ・エプシテイン オレグ 組み合わせ医薬組成物及び神経変性疾患に関連する疾患又は状態を治療する方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6015013185; 東方医学，２００７，ｖｏｌ．２３，　Ｎｏ．２，　ｐ．２１-３３ *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018150322A (ja) * 2010-07-15 2018-09-27 イリイチ・エプシテイン オレグ 組み合わせ医薬組成物及び泌尿生殖器系障害を治療する方法
JP2013533269A (ja) * 2010-07-21 2013-08-22 イリイチ・エプシテイン オレグ 組み合わせ医薬組成物及び呼吸器の疾患又は状態に関連する疾患及び状態を治療する方法
JP2013533268A (ja) * 2010-07-21 2013-08-22 イリイチ・エプシテイン オレグ 糖尿病及び代謝障害を治療する組み合わせ医薬組成物及び方法
JP2013536174A (ja) * 2010-07-21 2013-09-19 イリイチ・エプシテイン オレグ 組み合わせ医薬組成物並びに回転性めまい、動揺病及び自律神経血管ジストニアを治療する方法
JP2013537532A (ja) * 2010-08-06 2013-10-03 イリイチ・エプシテイン オレグ 感染性疾患を治療及び予防する組み合わせ医薬組成物及び方法
JP2016512893A (ja) * 2013-03-18 2016-05-09 イリイチ・エプシテイン オレグ 医薬の調節効力の程度を測定する方法
JP2022545178A (ja) * 2019-08-29 2022-10-26 イリイチ・エプシテイン オレグ 感染症を治療するための医薬及び方法
JP2024156824A (ja) * 2019-08-29 2024-11-06 イリイチ・エプシテイン オレグ 感染症を治療するための医薬及び方法

Also Published As

Publication number Publication date
EP2593477A2 (en) 2013-05-22
US8865163B2 (en) 2014-10-21
FR2962653A1 (fr) 2012-01-20
SE1350179A1 (sv) 2013-04-12
MY158183A (en) 2016-09-15
KR20140012009A (ko) 2014-01-29
ES2542042R1 (es) 2015-10-06
EE201300005A (et) 2013-08-15
DE112011102349T5 (de) 2013-04-18
DK201370078A (en) 2013-02-14
US20130017202A1 (en) 2013-01-17
CN103124742A (zh) 2013-05-29
LT2013015A (lt) 2013-11-25
SG187037A1 (en) 2013-02-28
PH12013500109A1 (en) 2015-07-03
FI20135146A7 (fi) 2013-02-15
AU2011278040A1 (en) 2013-03-07
CZ2013104A3 (cs) 2013-05-29
PE20131338A1 (es) 2013-11-18
EE05760B1 (et) 2016-03-15
AU2011278040B2 (en) 2016-06-02
NO20130219A1 (no) 2013-03-22
MX361778B (es) 2018-12-17
CA2805091A1 (en) 2012-01-19
ITTO20110641A1 (it) 2012-01-16
EA029400B1 (ru) 2018-03-30
EA201300133A1 (ru) 2014-03-31
GB2496076A (en) 2013-05-01
GB201302653D0 (en) 2013-04-03
CL2013000098A1 (es) 2015-01-16
WO2012007847A2 (en) 2012-01-19
LT5987B (lt) 2014-01-27
WO2012007847A3 (en) 2012-04-12
BR112013000841A2 (pt) 2016-06-07
ES2542042A2 (es) 2015-07-29
NZ606768A (en) 2015-08-28
MX2013000545A (es) 2013-10-28
FI20135146L (fi) 2013-02-15
AR082246A1 (es) 2012-11-21
GB2496076B (en) 2018-05-09

Similar Documents

Publication Publication Date Title
AU2011278040B2 (en) Pharmaceutical compositions and methods of treatment
MX2013000542A (es) Composicion farmaceutica combinada y metodos para el tratamiento de las enfermedades o condiciones funcionales del tracto gastrointestinal.
JP2016199571A (ja) 組み合わせ医薬組成物並びに回転性めまい、動揺病及び自律神経血管ジストニアを治療する方法
MX2013000808A (es) Un metodo para el tratamiento de la enfermedad de alzheimer.
MX2013000807A (es) Un metodo para el tratamiento del trastorno de hiperactividad con deficit de atencion.
WO2012014078A2 (en) Method of treatment of organic diseases of nervous system, psychoorganic syndrome and encephalopathy
JP2016216483A (ja) 活性化増強型抗体の効果を増大させる方法
RU2610438C2 (ru) Способ лечения патологического синдрома и лекарственное средство центрального и периферического действия для лечения патологического синдрома
RU2552221C2 (ru) Способ лечения ожирения и сопутствующих метаболических расстройств и лекарственное средство для лечения ожирения и сопутствующих метаболических расстройств
RU2582393C2 (ru) Способ лечения ожирения и сопутствующих метаболических расстройств

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140306

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150407

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151007

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160701

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160824

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20160930